Litcius/Paper detail

522MO Preliminary results of sintilimab (Sin)+bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial

X. Liu, Bocheng Xia, W. Zhang, LEYANG SUN, Chenwei Feng, Yisidan Huang, Yurui Gao, Jia kang Jiang, G. Li, Q. Gao

2022Annals of Oncology14 citationsDOI

Topics & Concepts

MedicineBevacizumabOncologyOvarian carcinomaOvarian cancerInternal medicineCancerChemotherapyOvarian cancer diagnosis and treatmentRenal cell carcinoma treatmentRenal and related cancers
522MO Preliminary results of sintilimab (Sin)+bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial | Litcius